Table 2.
Numbers of vertebral fracture events according to change in hip BMD at 6 months
| Treatment | Ibandronate | Risedronate | ||||
|---|---|---|---|---|---|---|
| Hip BMD at 6 months | ||||||
| ≤0 % | >0 to ≤3 % | >3 % | ≤0% | >0 to ≤3 % | >3 % | |
| (Months) | (n = 85) | (n = 150) | (n = 118) | (n = 116) | (n = 145) | (n = 89) |
| 12 | 10 (12.5 %) | 9 (6.3 %) | 6 (5.3 %) | 18 (15.9 %) | 16 (11.6 %) | 8 (9.3 %) |
| 24 | 14 (18.2 %) | 12 (8.8 %) | 7 (6.4 %) | 23 (20.7 %) | 17 (12.8 %) | 8 (9.4 %) |
| 36 | 19 (26.4 %) | 17 (13.3 %) | 12 (11.8 %) | 27 (27.0 %) | 22 (18.5 %) | 11 (14.1 %) |
| Treatment | Ibandronate | Risedronate | ||||
|---|---|---|---|---|---|---|
| Lumbar spine BMD at 6 monthsa | ||||||
| ≤0 % | >0 to ≤3 % | >3 % | ≤0 % | >0 to ≤3 % | >3 % | |
| (Months) | (n = 44) | (n = 81) | (n = 236) | (n = 61) | (n = 100) | (n = 190) |
| 12 | 3 (7.7 %) | 5 (6.3 %) | 11 (4.8 %) | 3 (5.2 %) | 10 (10.3 %) | 17 (9.3 %) |
| 24 | 5 (12.8 %) | 7 (9.2 %) | 15 (7.0 %) | 5 (9.1 %) | 10 (10.6 %) | 21 (11.7 %) |
| 36 | 6 (17.1 %) | 15 (22.4 %) | 23 (11.2 %) | 5 (10.0 %) | 11 (12.8 %) | 32 (20.3 %) |
aCases in which vertebral fractures occurred within the first 6 months were eliminated